Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


340B Squeeze Begins: New HRSA Head Doesn’t Tip His Hand

Executive Summary

HRSA Administrator George Sigounas made his public debut during the annual 340B coalition summer conference in Washington, DC. The setting was significant giving the prominence of the drug discount program on the Trump Administration agenda, but Sigounas didn’t offer much insight into the potential changes to come.

You may also be interested in...

Trump Administration's Pharma-Friendly Pricing Proposals Prompt Pushback

As work on policy development and executive orders continues, critics implore Trump to return to his "getting away with murder" roots.

340B Program Controls: House Committee Launches Investigation

Energy and Commerce Committee leadership requests audit records and other documents from the Health Resources and Services Administration to evaluate the effectiveness of its oversight of the program.

340B Reform May Return To Capitol Hill: Hearings Will Play To New HRSA Leadership

Rep. Chris Collins (R-NY) plans to introduced a bill to reform the 340B drug discount program in the coming weeks, and says he has a commitment from the House Energy & Commerce Committee leadership to consider the bill in hearings over the summer; that in turn may help shape HRSA’s oversight of the program in the Trump Administration.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts